What are we trying to change?

NAD+ is nicotinamide adenine dinucleotide, a coenzyme that cells use to process energy and support enzymes involved in DNA repair. It is not a peptide. Its role in basic biology is one reason researchers are interested in whether changing NAD+ availability could help in particular diseases.

The aging story needs more care. Lower NAD+ has been reported in some human tissues, but the pattern is not established uniformly across the body. A blood measurement cannot tell us that every tissue is deficient or that raising it will make someone healthier.[1]

NAD+, NR and NMN are different interventions

Nicotinamide riboside, or NR, and nicotinamide mononucleotide, or NMN, are precursors the body can use to make NAD+. Most supplement trials give a precursor by mouth. An NAD+ infusion delivers a different molecule by a different route. There are also studies of intravenous NR.

These distinctions matter when reading a benefit claim. A result from oral NMN cannot establish what an NAD+ drip does, and a faster infusion does not establish better energy, recovery or longevity. Even an increase in blood NAD+ does not guarantee a similar increase in muscle or brain tissue.[1]

What oral NMN trials found

In a 60-day randomized trial, 80 healthy middle-aged adults received placebo or one of three oral NMN doses. All three NMN groups had higher blood NAD concentrations and greater improvements in six-minute walking distance than placebo. The insulin-resistance measure HOMA-IR did not differ significantly. No safety problem emerged during that short trial. It was industry-funded and small, with 20 people per group.[2]

A separate 10-week trial in 25 postmenopausal women with prediabetes and overweight or obesity found improved muscle insulin sensitivity with NMN. Liver and fat-tissue insulin sensitivity, fasting glucose and body composition did not improve. The groups also differed in liver fat at baseline, a limitation discussed in a published comment. The authors replied that baseline muscle insulin sensitivity was similar between groups. The result supports further study of this particular population.[3][15][16]

Another trial gave a specific NMN formulation, MIB-626, to 30 adults with overweight or obesity for 28 days. It raised circulating NAD and reduced some measurements, including weight, diastolic blood pressure and LDL cholesterol. It did not improve insulin sensitivity, muscle strength, aerobic capacity or the other physical-performance measures. The positive and null findings both belong in the picture.[4]

NR has produced a walking signal and a negative Parkinson's result

The NICE trial randomized 90 people with peripheral artery disease to oral NR, NR plus resveratrol or placebo for six months. NR alone improved six-minute walking distance by an adjusted 17.6 metres relative to placebo. This met the trial's prespecified, exploratory one-sided significance threshold of P<0.10; the reported P value was 0.08. Resveratrol did not add benefit. A larger confirmatory trial is needed.[5]

The larger NOPARK study now has published results. It randomized 410 people with early Parkinson's disease to oral NR or placebo for 52 weeks, with 393 in the primary analysis. The main disease-severity score was worse with NR: the adjusted difference was 2.72 points in favour of placebo. This was statistically significant, although smaller than the study's cited threshold for a clinically important worsening. Four of five key secondary outcomes showed no significant difference; nonmotor symptom burden also favoured placebo.[6]

Serious adverse events were reported in 17 of 205 people receiving NR and 29 of 205 receiving placebo in the safety analysis. The trial therefore did not show an excess of serious adverse events, but its clinical results do not support NR as a disease-modifying treatment for Parkinson's.[6]

What about IV NAD+?

A 2019 pilot followed NAD+ and its metabolites during a six-hour infusion in eight men, with three saline controls. It helped describe what happened to the infused molecule. It did not test whether a course of infusions improves fatigue, cognition or aging.[7]

There are now randomized IV studies in specific cardiac settings. In a single-centre trial of 180 people with heart failure caused by ischemic cardiomyopathy, seven days of IV NAD+ alongside standard care produced a higher ejection fraction at one month. Ejection fraction measures how much blood the left ventricle pumps out with each beat. The difference in the six-month composite of major clinical events was not statistically significant.[8]

An October 2026 trial randomized 120 people after a particular type of heart attack and emergency coronary treatment. A seven-day IV NAD+ course produced a modest improvement in ejection fraction at 30 days, 56.32% versus 53.37% with placebo. Later major cardiac and cerebrovascular events did not differ significantly. Both cardiac trials used a specific 10 mg daily preparation in a hospital setting. Those results do not establish the benefit of substantially different wellness infusions.[9]

A 2026 retrospective clinic report compared six NAD+ infusion recipients with eight NR infusion recipients. NR infusions took less time and were better tolerated. All six NAD+ recipients reported infusion symptoms, including gastrointestinal discomfort and other unpleasant effects. This small, nonrandomized comparison of two IV products cannot establish that either is superior to an oral precursor or improves long-term health.[10]

Safety depends on the product and the setting

Several short oral trials reported similar adverse-event rates to placebo or no new safety signal. That is useful evidence within the participants and duration studied. It does not settle rare risks, years of use, or the safety of another formulation. The latest cardiac trial also reported one NAD+ recipient whose transient nausea led to stopping the infusion course.[2][4][9]

Injectable quality adds a separate concern. FDA has received reports of severe chills, shaking, vomiting and fatigue after NAD+ injections, with some people needing medical treatment. FDA described these reactions as consistent with excessive endotoxins and warned about using food-grade ingredients to prepare sterile products. These reports do not establish the rate of harm from every NAD+ preparation, but they rule out a blanket assurance that infusions are harmless.[11]

In the US, sale as a dietary supplement is not FDA approval of safety or effectiveness. A product's regulatory status and the evidence for a particular health claim are separate questions. Any proposed injection also needs its own product, route and local access requirements checked.[12]

How the findings fit together

Blood measurements

Oral NR and NMN can raise NAD-related measurements. Tissue responses and clinical effects vary.

Specific benefits

Small metabolic, walking and cardiac trials have reported selected positive findings.

Important null results

Several outcomes did not improve. NOPARK did not support clinical benefit in Parkinson's disease.

Longevity claims

The studies reviewed here have not established longer life or reversal of aging in people.

Questions that make a proposal easier to assess

The goal

  • What symptom or diagnosed condition are we trying to improve?
  • Which outcome would show a worthwhile change?
  • What established options should be considered first?

The preparation

  • Is this NAD+, NR or NMN, and how is it given?
  • Does the supporting study use the same product and route?
  • For an injection, how are sterility and endotoxins controlled?

The follow-up

  • How does my medical history affect the decision?
  • What adverse effects would prompt reassessment?
  • When will we decide whether there has been enough benefit to continue?

What to take away

The research supports more than a simple yes or no. Some interventions changed useful measurements in specific groups, while other outcomes were unchanged or worse. Start with the exact compound, route and health problem, then ask what the study actually measured.

Questions people ask

Does raising NAD+ reverse aging?

The human studies reviewed here have not established longer life or reversal of aging. A higher blood NAD measurement is a biological response, not proof of better health. Findings in a particular disease or tissue need to be assessed on their own.

Is IV NAD+ better than oral NR or NMN?

That has not been established for wellness or longevity. NAD+, NR and NMN are different molecules, and the route matters. Small comparisons of IV NAD+ with IV NR do not answer whether an infusion gives better long-term outcomes than an oral precursor.

Are NAD-related supplements and infusions safe?

Short oral trials provide some tolerability information, but they do not settle rare risks or years of use. Infusions can cause symptoms and carry preparation-quality risks. FDA has reported reactions after NAD+ injections consistent with excessive endotoxins.

Did the large Parkinson's trial show benefit from NR?

No. NOPARK randomized 410 people with early Parkinson's disease and found no clinical benefit after 52 weeks. The main disease-severity outcome statistically favoured placebo. These findings do not support NR as a disease-modifying Parkinson's treatment.

The evidence

Sources used for this article. The labels distinguish original trials, observational findings, research context and regulatory information.

Research review, 2025NAD+ precursor supplementation in human ageing: clinical evidence and challenges. PubMed 41083806
Randomized trial, 80 adultsThe efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. PubMed 36482258
Randomized trial, 25 womenNicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. PubMed 33888596
Randomized trial, 30 adultsNicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. PubMed 36740954
Randomized trial, 90 adultsNicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. PubMed 38871717
Phase 3 results, 2026Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. PubMed 42848371
Small infusion study, 2019A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. PubMed 31572171
Randomized cardiac trialEffect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. PubMed 40954388
Randomized cardiac trial, 2026Effect of Intravenous Nicotinamide Adenine Dinucleotide on Left Ventricular Function After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: A Randomized Controlled Trial. PubMed 42961639
Retrospective infusion studyIntravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. PubMed 41704678
FDA safety communicationFDA reminds compounders to use ingredients suitable for sterile compounding. FDA notice
FDA consumer informationQuestions and Answers on Dietary Supplements. FDA guidance
Trial registryNOPARK: A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease. NCT03568968
Trial registryEffect of NMN (Nicotinomide Mononucleotide) Supplementation on Cardiometabolic Function. NCT03151239
Published commentComment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women". PubMed 34326206
Authors' responseResponse to Comment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women". PubMed 34326209

Sources checked November 9, 2026. This is a focused review of the cited human studies and US safety information, not every NAD-related intervention or jurisdiction. Full reports were used where accessible; access limits and publication notices are recorded in the source review.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. NAD+ is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.